Stock Events

Stock Events

Eliem Therapeutics 

$5.11
34
-$0.05-0.97% Wednesday 20:00

Statistics

Day High
5.26
Day Low
5
52W High
11.55
52W Low
2.35
Volume
802,692
Avg. Volume
519,722
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

4MarExpected
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
-1.81
-1.21
-0.6
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
0Revenue
-35.12MNet Income

Analyst Ratings

$16.29Average Price Target
The highest estimate is 25.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELYM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen has a strong focus on neurological diseases, making it a direct competitor in the neurology space.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes works on central nervous system (CNS) diseases, overlapping with Eliem's focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Acadia Pharmaceuticals specializes in CNS disorders, including treatments for neurological and psychiatric conditions.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a broad portfolio that includes treatments for neurological conditions, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a wide range of neurology and psychiatry medications, making it a competitor in Eliem's market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diversified portfolio that includes drugs for neurological conditions, directly competing with Eliem.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a strong emphasis on neurodegenerative diseases and psychiatric disorders, areas of interest for Eliem.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a focus on CNS treatments, including generic and specialty medicines that compete with Eliem.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for neurological and mental health conditions, competing with Eliem.

About

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Show more...
CEO
Employees
9
Country
US
ISIN
US28658R1068

Listings

XNAS
US
CLYM
BOATS
BOATS
CLYM.BOATS

0 Comments

Share your thoughts

FAQ

What is Eliem Therapeutics stock price today?▼
The current price of ELYM is $5.11 USD — it has decreased by -0.97% in the past 24 hours. Watch Eliem Therapeutics stock price performance more closely on the chart.
What is Eliem Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Eliem Therapeutics stocks are traded under the ticker ELYM.
What is Eliem Therapeutics revenue for the last year?▼
Eliem Therapeutics revenue for the last year amounts to 0 USD.
What is Eliem Therapeutics net income for the last year?▼
ELYM net income for the last year is -35.12M USD.
How many employees does Eliem Therapeutics have?▼
As of April 02, 2026, the company has 9 employees.
In which sector is Eliem Therapeutics located?▼
Eliem Therapeutics operates in the Professional, Scientific, and Technical Services sector.
When did Eliem Therapeutics complete a stock split?▼
Eliem Therapeutics has not had any recent stock splits.